The effect of low-dose atorvastatin on circulating monocyte chemoattractant protein-1 in patients with type 2 diabetes complicated by hyperlipidemia

Metabolism: Clinical and Experimental

Volumn 54, Issue 9, 2005, Pages 1225-1229

  Takebayashi, Kohzo ^a   Matsumoto, Sachiko ^a   Wakabayashi, Sadao ^a   Inukai, Yoshihisa ^a   Matsutomo, Rika ^a   Aso, Yoshimasa ^a   Inukai, Toshihiko ^a  

^a DOKKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LOW DRUG DOSE; MALE; MEASUREMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE;

ADULT; AGED; C-REACTIVE PROTEIN; CHEMOKINE CCL2; DIABETES MELLITUS, TYPE 2; FEMALE; FIBRINOGEN; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INFLAMMATION; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYRROLES;

EID: 23944438407     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2005.04.008     Document Type: Article

References (25)

1. E.S. Ford Body mass index, diabetes, and C-reactive protein among U.S. adults Diabetes Care 22 1999 1971 1977
2. M. Frohlich, A. Imhof, and G. Berg Association between C-reactive protein and features of the metabolic syndrome: a population-based study Diabetes Care 23 2000 1835 1839
3. J.C. Pickup, M.B. Mattock, and G.D. Chusney NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X Diabetologia 40 1997 1286 1292
4. H. Baumann, and J. Gauldie Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation Mol Biol Med 7 1990 147 159
5. J.A. Lemos, D.A. Morrow, and M.S. Sabatine Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes Circulation 107 2003 690 695
6. L. Piemonti, G. Calori, and A. Mercalli Fasting plasma leptin, tumor necrosis factor-α receptor 2, and monocyte chemoattractant protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women Diabetes Care 26 2003 2883 2889
7. N.A. Nelken, S.R. Coughlin, D. Gordon, and J.N. Wilcox Monocyte chemoattractant protein-1 in human atheromatous plaques J Clin Invest 88 1991 1121 1127
8. M. Namiki, S. Kawashima, and T. Yamashita Local overexpression of monocyte chemoattractant protein-1 at vessel wall induces infiltration of macrophages and formation of atherosclerotic lesion: synergism with hypercholesterolemia Arterioscler Thromb Vasc Biol 22 2002 115 120
9. D. Walmsely, K.K. Hampton, and P.J. Grant Contrasting fibrinolytic responses in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes Diabet Med 8 1991 954 959
10. G.J. Blake, and P.M. Ridker Novel clinical markers of vascular wall inflammation Circ Res 89 2001 763 771
11. T.A. Libermann, and D. Baltimore Activation of interleukin-6 gene expression through the NFκB transcription factor Mol Cell Biol 10 1990 2327 2334
12. T. Martin, P.M. Cardarelli, and G.C. Parry Cytokine induction of monocyte chemoattractant protein-1 gene expression in human endothelial cells depends on the cooperative action of NFκB and AP-1 Eur J Immunol 27 1997 1091 1099
13. A. Bierhaus, S. Schiekofer, and M. Schwaninger Diabetes-associated sustained activation of the transcription factor nuclear factor-κB Diabetes 50 2001 2792 2808
14. M. Ortego, C. Bustos, and M.A. Hernandez-Presa Atorvastatin reduces NFκB activation and chemokine expression in vascular smooth muscle cells Atherosclerosis 147 1999 253 261
15. I. Jialal, D. Stein, D. Balis, S.M. Grundy, B. Adam-Huet, and S. Devarai Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive levels Circulation 103 2001 1933 1935
16. M.A. Albert, E. Danielson, and N. Rifai Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study JAMA 286 2001 64 70
17. H.M. Colhoun, D.J. Betteridge, and P.N. Durrington Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial Lancet 364 2004 685 696
18. K.C.B. Tan, W.S. Chow, and S.C.F. Tam Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus J Clin Endocrinol Metab 87 2002 563 568
19. M.A. Van de Ree, M.V. Huisman, and H.M.G. Princen Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus Atherosclerosis 166 2003 2129 2135
20. Japan Atherosclerosis Society (JAS) Japan Atherosclerosis Society (JAS) guidelines for diagnosis and treatment of atherosclerotic cardiovascular disease 2002 Japan Atherosclerosis Society Tokyo [in Japanese]
21. A. Von Clauss Gerinnungsphysiolgische schnellmethode zur bestimmung des fibrinogens Acta Haematol 17 1957 237 246
22. Z.M. Xu, S.P. Zhao, and Q.Z. Li Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome Clin Chem Acta 388 2003 17 24
23. R. Dechend, A. Fiebeler, and J.K. Park Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor Circulation 104 2001 576 581
24. V. Pasceri, J.S. Cheng, and J.T. Willerson Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs Circulation 103 2001 2531 2534
25. S. Devaraji, D.Y. Xu, and I. Jialal C-reactive protein increase plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherosclerosis Circulation 107 2003 398 404